679 related articles for article (PubMed ID: 28104919)
1. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
2. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
[TBL] [Abstract][Full Text] [Related]
3. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
[TBL] [Abstract][Full Text] [Related]
5. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
6. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
7. Detection of clonal plasma cells in POEMS syndrome using multiparameter flow cytometry.
Ishii A; Tsukamoto S; Mimura N; Miyamoto-Nagai Y; Isshiki Y; Matsui S; Nakao S; Shibamiya A; Hino Y; Kayamori K; Oshima-Hasegawa N; Muto T; Takeda Y; Suichi T; Misawa S; Ohwada C; Yokote K; Kuwabara S; Nakaseko C; Takamatsu H; Sakaida E
Sci Rep; 2024 May; 14(1):10362. PubMed ID: 38710832
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease in multiple myeloma: ready for clinical practice?
Burgos L; Puig N; Cedena MT; Mateos MV; Lahuerta JJ; Paiva B; San-Miguel JF
J Hematol Oncol; 2020 Jun; 13(1):82. PubMed ID: 32571377
[TBL] [Abstract][Full Text] [Related]
9. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.
Mina R; Oliva S; Boccadoro M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32645952
[TBL] [Abstract][Full Text] [Related]
10. Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.
Romano A; Palumbo GA; Parrinello NL; Conticello C; Martello M; Terragna C
Front Oncol; 2019; 9():699. PubMed ID: 31482061
[TBL] [Abstract][Full Text] [Related]
11. Potential future direction of measurable residual disease evaluation in multiple myeloma.
Mohty M; Avet-Loiseau H; Malard F; Harousseau JL
Blood; 2023 Nov; 142(18):1509-1517. PubMed ID: 37471603
[TBL] [Abstract][Full Text] [Related]
12. [Minimal residual disease assessment and progress in multiple myeloma].
Zhou HX; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):203-208. PubMed ID: 38604801
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice.
Gupta R; Jevremovic D; Mathew SJ; Kumar S
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e88-e95. PubMed ID: 38142203
[TBL] [Abstract][Full Text] [Related]
14. Advances in minimal residual disease monitoring in multiple myeloma.
Wijnands C; Noori S; Donk NWCJV; VanDuijn MM; Jacobs JFM
Crit Rev Clin Lab Sci; 2023 Nov; 60(7):518-534. PubMed ID: 37232394
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2014 Oct; ():. PubMed ID: 25349085
[TBL] [Abstract][Full Text] [Related]
16. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
Guan L; Su W; Zhong J; Qiu L
Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
[TBL] [Abstract][Full Text] [Related]
17. Current Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in Korea.
Park M; Lim J; Ahn A; Oh EJ; Song J; Kim KH; Han JY; Choi HW; Park JH; Shin KH; Kim H; Kim M; Hwang SH; Kim HY; Cho D; Kang ES
Ann Lab Med; 2024 May; 44(3):222-234. PubMed ID: 38145891
[TBL] [Abstract][Full Text] [Related]
18. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.
Wijnands C; Langerhorst P; Noori S; Keizer-Garritsen J; Wessels HJCT; Gloerich J; Bonifay V; Caillon H; Luider TM; van Gool AJ; Dejoie T; VanDuijn MM; Jacobs JFM
Clin Chem Lab Med; 2024 Feb; 62(3):540-550. PubMed ID: 37823394
[TBL] [Abstract][Full Text] [Related]
19. Automated EuroFlow approach for standardized in-depth dissection of human circulating B-cells and plasma cells.
Delgado AH; Fluxa R; Perez-Andres M; Diks AM; van Gaans-van den Brink JAM; Barkoff AM; Blanco E; Torres-Valle A; Berkowska MA; Grigore G; van Dongen JJM; Orfao A
Front Immunol; 2023; 14():1268686. PubMed ID: 37915569
[TBL] [Abstract][Full Text] [Related]
20. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.
Merz M; Hu Q; Merz AMA; Wang J; Hutson N; Rondeau C; Celotto K; Belal A; Alberico R; Block AW; Mohammadpour H; Wallace PK; Tario J; Luce J; Glenn ST; Singh P; Samur M; Munshi N; Liu S; McCarthy PL; Wei L; Hillengass J
Blood Adv; 2023 Mar; 7(5):718-733. PubMed ID: 35868022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
